Technology ID

Detection of Retroviruses and HIV-1 Groups -M and -O Discrimination within Clinical Serum Samples

Lead Inventor
Heneine, Walid (CDC)
Folks, Thomas (CDC)
Yamamoto, Shinji
Switzer, William (CDC)
Research Materials
Occupational Safety and Health
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
Lead IC
CDC researchers have developed methods for detecting retroviruses within a patient blood sample and discriminating HIV-1 samples within serum specimens. HIV-1 can be genetically classified into two major groups, group M (major) and Group O (outlier) with group O comprising all divergent viruses that do not cluster with group M. The identification of group O infections raised public health concerns about the safety of the blood supply because HIV-1 screening by group M-based serologic tests does not consistently detect group O infection.

The assay is based on the selective inhibition of Amp-RT reactivity of Group M viruses by nevirapine, a non-nucleoside RT inhibitor. Group O viruses can be generically identified by the resistance of their Amp-RT activity to nevirapine. The assay can be used to screening of the blood supply and to rapidly differentiate group M from group O virus.
Commercial Applications
  • Clinical monitoring of individual patient antiretroviral therapy
  • HIV/AIDS public health programs
  • Surveillance of retroviral drug resistance
  • Screening of blood donations
Competitive Advantages
  • Rapid diagnostic which greatly reduces time and labor for improved clinical monitoring of HIV treatment
  • Ready for commercialization
  • Easily adapted to kit format
  • Assists continued usefulness of common antiretroviral therapeutics
  • Useful for high-throughput serum samples screening
Licensing Contact:
Specialist (ALS), Admin. Licensing